FDA Approves MYQORZO Label Update With MAPLE-HCM Results

Share on Social Media

Cytokinetics MYQORZO aficamten prescribing information update incorporating Phase 3 MAPLE-HCM trial results

Cytokinetics secures FDA approval to update MYQORZO prescribing information with Phase 3 MAPLE-HCM results comparing aficamten with metoprolol in obstructive HCM.

Written By: Kalyani Boharapi, M. Pharm (RA)

Reviewed By: Pharmacally Editorial Team

Cytokinetics, Inc. announced on November 16, 2026, that the US Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to update the US Prescribing Information for MYQORZO® (aficamten), incorporating findings from the Phase 3 MAPLE-HCM trial. The study compared aficamten monotherapy with metoprolol monotherapy in adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), demonstrating greater improvements in exercise capacity and several secondary clinical measures with aficamten.

The label update makes MYQORZO the only cardiac myosin inhibitor with comparative evidence against a beta-blocker included in its US prescribing information, according to Cytokinetics.

Phase 3 MAPLE-HCM Demonstrates Improvement in Exercise Capacity

MAPLE-HCM (NCT05767346) was an international, multicentre, randomised, double-blind, double-dummy, active-controlled Phase 3 trial involving 175 adults with symptomatic oHCM. Participants received either aficamten (5–20 mg daily; n=88) or metoprolol (50–200 mg daily; n=87) for 24 weeks.

The primary endpoint assessed the change from baseline in peak oxygen uptake (pVO₂) at Week 24. Aficamten met the primary endpoint, demonstrating a significantly greater improvement than metoprolol. Mean pVO₂ increased by 1.1 mL/kg/min with aficamten, compared with a decrease of 1.2 mL/kg/min with metoprolol. The least-squares mean between-group difference was 2.3 mL/kg/min (95% CI, 1.5–3.1; P<0.001).

The treatment effect was consistent across prespecified subgroups, including newly diagnosed and treatment-naïve participants.

Aficamten also demonstrated statistically significant improvements in five of six secondary endpoints: New York Heart Association (NYHA) Functional Class, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), N-terminal pro-B-type natriuretic peptide (NT-proBNP), post-Valsalva left ventricular outflow tract (LVOT) gradient and left atrial volume index. The sixth endpoint, left ventricular mass index, did not show a significant between-group difference.

These findings were originally published in the New England Journal of Medicine in August 2025. Their incorporation into the US prescribing information provides clinicians with peer-reviewed comparative evidence when considering treatment options for symptomatic oHCM.

Safety Findings and Prescribing Information

Overall adverse-event rates were similar between the aficamten and metoprolol groups. Hypertension was reported more frequently with aficamten, whereas dizziness was more frequent with metoprolol. The updated prescribing information reports hypertension in 15% of participants receiving aficamten compared with 3% receiving metoprolol.

MYQORZO carries a boxed warning for heart failure due to systolic dysfunction. Aficamten reduces left ventricular ejection fraction (LVEF), requiring echocardiographic assessment before and during treatment. Initiation is not recommended in patients with an LVEF below 55%. The dose should be decreased if LVEF falls below 50% but remains at least 40%, and treatment should be interrupted if LVEF falls below 40% or patients develop heart failure symptoms or worsening clinical status due to systolic dysfunction.

The medicine is available through the restricted MYQORZO Risk Evaluation and Mitigation Strategy (REMS) programme and is contraindicated with concomitant rifampin use.

Regulatory Background and Clinical Development

Aficamten is a cardiac myosin inhibitor that reduces cardiac contractility and consequently decreases LVOT obstruction in patients with oHCM. MYQORZO is indicated in adults with symptomatic oHCM to improve functional capacity and symptoms.

The FDA initially approved MYQORZO in December 2025 based on results from the Phase 3 SEQUOIA-HCM trial. The medicine has also received approvals in China, the European Union, the United Kingdom and Canada.

Aficamten’s broader clinical development programme includes ACACIA-HCM, a completed Phase 3 trial in non-obstructive HCM (nHCM), CEDAR-HCM in paediatric patients with oHCM and FOREST-HCM, an open-label extension study. Following positive ACACIA-HCM results, Cytokinetics plans to submit a separate sNDA for nHCM in the fourth quarter of 2026.

Clinical Significance

The MAPLE-HCM findings provide head-to-head Phase 3 evidence that aficamten monotherapy improves exercise capacity more than metoprolol monotherapy in adults with symptomatic oHCM. The between-group difference in peak oxygen uptake, alongside improvements in symptom measures, cardiac biomarkers and LVOT gradient, strengthens the clinical evidence supporting aficamten’s role in oHCM management.

The FDA-approved label update is particularly relevant because beta-blockers have traditionally been used as initial pharmacological treatment for symptomatic oHCM. However, the findings should be interpreted within the context of a 24-week trial and do not independently establish long-term comparative outcomes or superiority across all clinical settings.

Reference

Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM, Cytokinetics, 16 November 2026

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults with Symptomatic oHCM (MAPLE-HCM), ClinicalTrials.gov ID NCT05767346

About the Writer

Kalyani Boharapi (LinkedIn) is a pharmacy professional and healthcare writer currently pursuing an M.Pharm in Regulatory Affairs at Dr. D. Y. Patil College of Pharmacy, with interests in pharmaceutical regulations, drug development, and healthcare innovation. She has academic exposure to dossier preparation, scientific writing, and regulatory documentation. Kalyani has also completed certification courses in Generative AI, AI in Pharma, and Bioinformatics, and actively participates in pharmaceutical conferences to stay updated with emerging trends and advancements in the healthcare and pharmaceutical industry.


Share on Social Media
Scroll to Top